Phase II Study of the Lysine-Specific Demethylase 1 Inhibitor Bomedemstat for Essential Thrombocythemia

In a Phase II trial, participants with essential thrombocythemia who required cytoreduction and had inadequate response to, or were intolerant of, ≥1 standard therapy received bomedemstat at a starting dose of 0.6 mg/kg per day, titrated to achieve a target platelet count